



# Provider Notice

November 4, 2024

## Procedure Codes Removed from Prior Authorization List- Effective January 1, 2025

CountyCare Health Plan is committed to providing an efficient and consistent Utilization Management (UM) experience for our members and providers. We continue to review our prior authorization lists to ensure they are up to date with current fee schedules.

The following codes are being added to the Prior Authorization Lookup but will require prior authorization and **prior authorization will be performed by Evolent Specialty Services (Formerly New Century Health).**

Code Type	Code	Code Description	PA DECISION
CPT	0444U	Oncology (solid organ neoplasia), targeted genomic sequence analysis panel of 361 genes, interrogation for gene fusions, translocations, or other rearrangements, using DNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue, report of clinically significant variant(s)	Yes
CPT	0448U	Oncology (lung and colon cancer), DNA, qualitative, next-generation sequencing detection of single-nucleotide variants and deletions in EGFR and KRAS genes, formalin-fixed paraffin-embedded (FFPE) solid tumor samples, reported as presence or absence of targeted mutation(s), with recommended therapeutic options	Yes
CPT	0451U	Oncology (multiple myeloma), LC-MS/MS, peptide ion quantification, serum, results compared with baseline to determine monoclonal paraprotein abundance	Yes
CPT	0453U	Oncology (colorectal cancer), cell-free DNA (cfDNA), methylation-based quantitative PCR assay (SEPTIN9, IKZF1, BCAT1, Septin9-2, VAV3, BCAN), plasma, reported as presence or absence of circulating tumor DNA (ctDNA)	Yes
CPT	0458U	Oncology (breast cancer), S100A8 and S100A9, by enzyme-linked immunosorbent assay (ELISA), tear fluid with age, algorithm reported as a risk score	Yes
CPT	0460U	Oncology, whole blood or buccal, DNA single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, with variant analysis and reported phenotypes	Yes

CPT	0461U	Oncology, pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, whole blood or buccal swab, with variant analysis, including impacted gene-drug interactions and reported phenotypes	Yes
CPT	0465U	Oncology (urothelial carcinoma), DNA, quantitative methylation-specific PCR of 2 genes (ONECUT2, VIM), algorithmic analysis reported as positive or negative	Yes
CPT	0467U	Oncology (bladder), DNA, next-generation sequencing (NGS) of 60 genes and whole genome aneuploidy, urine, algorithms reported as minimal residual disease (MRD) status positive or negative and quantitative disease burden	Yes
CPT	0470U	Oncology (oropharyngeal), detection of minimal residual disease by next-generation sequencing (NGS) based quantitative evaluation of 8 DNA targets, cell-free HPV 16 and 18 DNA from plasma	Yes
CPT	0471U	Oncology (colorectal cancer), qualitative real-time PCR of 35 variants of KRAS and NRAS genes (exons 2, 3, 4), formalin- fixed paraffin-embedded (FFPE), predictive, identification of detected mutations	Yes
CPT	0473U	Oncology (solid tumor), next-generation sequencing (NGS) of DNA from formalin-fixed paraffin-embedded (FFPE) tissue with comparative sequence analysis from a matched normal specimen (blood or saliva), 648 genes, interrogation for sequence variants, insertion and deletion alterations, copy number variants, rearrangements, microsatellite instability, and tumor-mutation burden	Yes
CPT	0498U	Onc clrct ngs mut detc 43gen	Yes
CPT	0499U	Onc clrct&lng dna ngs 8gene	Yes
HCPCS	C9169	Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 mcg	Yes
HCPCS	C9170	Injection, tarlatamab-dlle, 1 mg	Yes
HCPCS	J0209	Injection, sodium thiosulfate (Hope), 100 mg	Yes
HCPCS	J1434	FOSAPREPITANT INJECTION	Yes
HCPCS	J2277	MOTIXAFORTIDE INJECTION	Yes

HCPCS	J2468	PALONOSETRON HYDROCHLORIDE INJECTION	Yes
HCPCS	J3247	Injection, secukinumab, intravenous, 1 mg	Yes
HCPCS	J3263	TORIPALIMAB-TPZI INJECTION	Yes
HCPCS	J7171	ADAMTS13 RECOMBINANT-KRHN INJECTION	Yes
HCPCS	J8522	Capecitabine, oral, 50 mg	Yes
HCPCS	J8611	METHOTREXATE ORAL SOLUTION	Yes
HCPCS	J9073	CYCLOPHOSPHAMIDE (INGENUS) INJECTION	Yes
HCPCS	J9249	MELPHALAN (APOTEX) INJECTION	Yes
HCPCS	J9329	Injection, tislelizumab-jsgr, 1mg	Yes
HCPCS	J9361	EFBEMALENOGRASTIM ALFA-VUXW INJECTION	Yes
HCPCS	Q5121	INFLIXIMAB-AXXQ INJECTION	Yes
HCPCS	Q5136	Injection, denosumab-bbdz (Jubbonti/Wyost), biosimilar, 1 mg	Yes

**This notice is intended to provide guidance for In-Network facilities. All Out of Network requests are subject to prior authorization along with Medical Director review and may be redirected to an In-Network facility.**

To access [Evolent Specialty \(New Century Health\) Portal](#) for authorization entry, please follow the steps below to obtain authorizations:

- Login Evolent Specialty Provider portal: <https://my.newcenturyhealth.com/>.
- New user can request access and training by contacting Latonia Bradshaw Sr. Provider Network Manager at [lbradshaw@newcenturyhealth.com](mailto:lbradshaw@newcenturyhealth.com) or by phone at 562.237.3419.
- Training is available for all new staff members and refresher courses for existing staff as needed.

### Contact Us

If you need additional assistance on how to use the portal, please contact CountyCare Provider Relations (PR) at [CountyCareProviderServices@cookcountyhhs.org](mailto:CountyCareProviderServices@cookcountyhhs.org) or CountyCare Provider Services at **312-864-8200, Option 6**. You can also use our Interactive Voice Response (IVR) system to verify eligibility. The Provider Services Representatives can assist you with eligibility and claim status. They can also connect you with your assigned PR Representative.